Skip to the reading
Sermorelin Then & Now

The sources behind Sermorelin’s changing story

These links follow the same questions as the rest of the guide. Some explain the children’s treatment. Others cover adult studies or FDA decisions. Each belongs to a particular question; none gives a blanket answer about a prescription today.

Children’s studies and earlier use

  • The first-year growth study

    Thorner and colleagues, 1996. Children with growth hormone deficiency grew faster. No untreated comparison group; final adult height wasn’t established.

  • The nasal pilot

    Hümmelink and colleagues, 1993. Height growth didn’t speed up with the nasal preparation tested in this small children’s study.

  • The pediatric review

    Prakash and Goa, 1999. Explains earlier uses and reports flushing and injection-site pain.

  • The children’s follow-up

    Lanes and Carrillo, 1994. Antibodies appeared in some children without seeming to interfere with growth.

Adult studies and safety questions

  • The older-men hormone study

    Corpas and colleagues, 1992. Hormone measurements changed during a short trial. This wasn’t proof of reversing aging.

  • The nightly adult study

    Vittone and colleagues, 1997. Growth hormone rose overnight; measured muscle and fat didn’t change.

  • The tesamorelin thinking trial

    Baker and colleagues, 2012. The medicine was tesamorelin, rather than Sermorelin. Its result can’t be transferred between drugs.

  • The absorption study

    Wilton and colleagues, 1993. Tested intravenous and nasal forms in healthy men; nasal absorption was low.

  • The FDA’s growth hormone safety discussion

    FDA, 2024. A review of related peptides discusses growth hormone label warnings, rather than measured adult Sermorelin risks.

Approvals and today’s prescription questions

What can a source answer?

A study can tell us what happened to the people who took part. Its result doesn’t automatically carry over to a different age group, medicine or way of giving it. The adult research page shows why those details matter.

Government records need the same care. The FDA’s finding about an old product leaving sale isn’t an approval of a new compounded one. The chronology follows those events in order, and the access page explains what they mean for a present prescription discussion.